Structure-based drug design of antirhinoviral compounds.
Improved knowledge of rhinovirus structures makes it possible to identify three promising targets for broad-spectrum antirhinoviral drugs.
Giranda
V L
VL
Sterling Winthrop Pharmaceuticals Research Division, Collegeville, PA 19426-0900.
D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D002213:Capsid / Q000187:drug effects / Q000378:metabolism; D036022:Capsid Proteins; D003139:Common Cold / Q000188:drug therapy; D015195:Drug Design; D006801:Humans; D011991:Receptors, Virus / Q000187:drug effects / Q000378:metabolism; D012229:Rhinovirus / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure
D000998:Antiviral Agents; D036022:Capsid Proteins; D011991:Receptors, Virus